Thermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026

About this update from Thermo Fisher Scientific Inc

Key facts: WALTHAM, Mass., July 27, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, will showcase its latest diagnostic innovations, recent regulatory milestones and expanded capabilities at the Association for Diagnostics & Laboratory Medicine Conference (ADLM), July 26-30, 2026, in Anaheim, Calif. Spanning specialty diagnostics, quality management and the full diagnostic continuum, Thermo Fisher's presence at ADLM 2026 reflects its ongoing commitment to addressing unmet clinical needs with reliable, purpose-built diagnostic and workflow solutions. "Laboratories today face growing pressure to deliver faster, more accurate results while managing operational complexity," said Puneet Sarin, senior vice president and president, specialty diagnostics at Thermo Fisher. "At the same time, the traditional boundaries between research, translational medicine and diagnostics continue to blur as science advances and healthcare evolves. With the breadth of our diagnostics portfolio—including instruments, assays and digital solutions—Thermo Fisher is uniquely positioned to help laboratories accelerate innovation, enable precision medicine and deliver the reliable insights clinicians need to improve patient care." Innovation to Address Unmet Clinical Needs Thermo Fisher's EXENT® Solution, a fully integrated and automated mass spectrometry platform designed to aid in the diagnosis of multiple myeloma and related disorders, recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA). According to the International Myeloma Foundation (IMF), more than 176,000 people worldwide are diagnosed with multiple myeloma each year, yet the current diagnostic pathway can be slow and uncertain, often relying on subjective interpretation of test results. By combining increased sensitivity with automated workflows, the EXENT System helps clinical laboratories deliver accurate results, supporting fast, confident diagnoses and more informed clinical decision-making. The system is currently available for clinical use in Australia, Belgium, Brazil, Canada, France, Germany, Italy, the Netherlands, New Zealand, Spain, Switzerland, the United Kingdom and the United States. In oncology, the Oncomine™ Dx Express Test (ODxET) on the Ion Torrent™ Genexus™ Dx Integrated Sequencer received FDA approval in 2025 as a companion diagnosti...

View stock analysis, news, and events for Thermo Fisher Scientific Inc